Innovative Technology Platform HealthTell specializes in advanced immune profiling assays with broad applications in drug discovery, therapeutic monitoring, and disease characterization. This presents opportunities to partner with biopharmaceutical companies seeking high-depth immune analysis tools for their R&D pipelines.

Growing Market Presence With a workforce of 51 to 200 employees and recent leadership appointments, HealthTell is expanding its capabilities and establishing a strong foothold in the biotech sector, making it a promising candidate for collaborations and strategic alliances.

Funding & Revenue Potential Having secured $26 million in funding and generating between $1M and $10M in revenue, HealthTell is positioned for growth and investment opportunities, especially in areas aligned with immune-related diagnostics and personalized medicine.

Focus on Disease Applications The company's technology targets autoimmune, cancer, CNS, and infectious diseases, highlighting potential sales avenues in clinical research, diagnostic development, and therapeutic response monitoring across these high-impact areas.

Targeted Client Base Operating a state-of-the-art laboratory and serving biopharmaceutical and research communities, HealthTell's client base includes innovative pharma firms and research institutions, offering pathways for collaborations, licensing, and contract research services.